trial
as of 2026-07-01Siltuximab in Schizophrenia
NCTId NCT02796859
at a glance
Phase 1, Phase 2 · Unknown
Enrollment 30 (estimated)
Sponsored by Brian Miller
Primary completion 2023-12-31
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1, Phase 2
Status
Unknown
Enrollment
30 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2016-05
Primary completion
2023-12-31
Eligibility
ALL · 18 Years · 55 Years
Interventions & indications
Sponsors
Brian MillerLead Sponsor
Stanley Medical Research InstituteCollaborator
Sites
1 total
Augusta, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
30
Phase
PHASE1,PHASE2
Primary Completion Date
2023-12-31
Status
UNKNOWN
relationships
The graph out of here
drug
drug
lead_sponsor
company
collaborator
indication